BioStratum Incorporated Adds Former Glaxo President D'Alonzo and Memorial Sloan-Kettering President Emeritus Marks to Board of Directors

-- Pharmaceutical Executive and Cancer Research Leader Bring Extensive

Experience to Company --



Apr 26, 2001, 01:00 ET from BioStratum Incorporated

    RESEARCH TRIANGLE PARK, N.C., April 26 /PRNewswire/ -- BioStratum
 Incorporated, a worldwide leader in drug development based on basal lamina
 research, announced today the election of two new directors.  Joining the
 Company's Board are: Thomas W. D'Alonzo, J.D., former President of Glaxo Inc.,
 and Paul A. Marks, M.D., Ph.D., President Emeritus of Memorial Sloan-Kettering
 Cancer Center.
     "Thomas and Paul bring enormous value to BioStratum," said Dr. Claus Kuhl,
 BioStratum President and CEO.  "Their insights and guidance will be invaluable
 as we move our products through the clinic and towards commercialization.
 Thomas' nearly 20 years as a pharmaceutical executive have given him a deep
 understanding of the industry, and Paul is internationally recognized for his
 lifelong work in cancer research and patient care."
     Pyridorin(TM), BioStratum's lead drug candidate currently in Phase II
 clinical trials, is targeted at treating diabetic kidney disease.
 Angiocol(TM), a late-stage preclinical compound that BioStratum expects will
 enter Phase I clinical trials in late 2001, is an anti-angiogenesis agent that
 has dramatically inhibited the growth and spread of tumors in certain in vivo
 models.
     Mr. D'Alonzo most recently served as President of Pharmaceutical Product
 Development Inc. (PPD), a multinational clinical research organization.
 Previously, he was President of Glaxo Inc. and of GenVec Inc.  He also serves
 on the Boards of Directors of Salix Pharmaceuticals Inc., Amarillo Biosciences
 Inc., and Accordant Healthcare Inc.
     Dr. Marks, a recognized leader in the cancer field, was President and
 Chief Executive Officer of Memorial Sloan-Kettering Cancer Center in New York
 from 1980 to 1999.  Previously Dr. Marks held teaching and research positions
 at Columbia University for 25 years.  In addition, he has served as an advisor
 to the National Institutes of Health, the National Science Foundation, and
 other governmental bodies.  He is a member of the National Academy of Sciences
 and the Institute of Medicine, as well as a Fellow of the American Academy of
 Arts and Sciences.  He has received numerous honors and awards, including the
 President's National Medal of Science.  In addition, he has published more
 than 375 scientific articles in various scholarly journals.
 
     About BioStratum
     BioStratum is a worldwide leader in drug development based on basal lamina
 research.  The Company is developing a pipeline of drugs based on the basal
 lamina's central role in many diseases.  Pyridorin(TM), the Company's lead
 drug candidate, is currently advancing through Phase II clinical trials for
 diabetic kidney disease. BioStratum is working toward having Angiocol(TM) --
 its proprietary anti-angiogenesis drug candidate that dramatically inhibits
 the growth of tumors in animal models of cancer -- enter Phase I clinical
 trials in late 2001.  BioStratum is also developing novel therapeutics for
 other kidney diseases, tissue regeneration, and autoimmune diseases.
 Headquartered in Research Triangle Park, North Carolina, BioStratum's research
 and development operations are further extended through multiple
 collaborations with leading basal lamina research centers.  For further
 information, please visit www.biostratum.com.
 
     CONTACT:
      BioStratum Incorporated
      Mike Klodnicki
      Director of Investor Relations and
      Corporate Communications
      (919) 433-1038
      mklodnicki@BioStratum.com
 
      Feinstein Kean Healthcare
      Harriet Ullman
      (617) 577-8110
      hullman@fkhealth.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X14735637
 
 

SOURCE BioStratum Incorporated
    RESEARCH TRIANGLE PARK, N.C., April 26 /PRNewswire/ -- BioStratum
 Incorporated, a worldwide leader in drug development based on basal lamina
 research, announced today the election of two new directors.  Joining the
 Company's Board are: Thomas W. D'Alonzo, J.D., former President of Glaxo Inc.,
 and Paul A. Marks, M.D., Ph.D., President Emeritus of Memorial Sloan-Kettering
 Cancer Center.
     "Thomas and Paul bring enormous value to BioStratum," said Dr. Claus Kuhl,
 BioStratum President and CEO.  "Their insights and guidance will be invaluable
 as we move our products through the clinic and towards commercialization.
 Thomas' nearly 20 years as a pharmaceutical executive have given him a deep
 understanding of the industry, and Paul is internationally recognized for his
 lifelong work in cancer research and patient care."
     Pyridorin(TM), BioStratum's lead drug candidate currently in Phase II
 clinical trials, is targeted at treating diabetic kidney disease.
 Angiocol(TM), a late-stage preclinical compound that BioStratum expects will
 enter Phase I clinical trials in late 2001, is an anti-angiogenesis agent that
 has dramatically inhibited the growth and spread of tumors in certain in vivo
 models.
     Mr. D'Alonzo most recently served as President of Pharmaceutical Product
 Development Inc. (PPD), a multinational clinical research organization.
 Previously, he was President of Glaxo Inc. and of GenVec Inc.  He also serves
 on the Boards of Directors of Salix Pharmaceuticals Inc., Amarillo Biosciences
 Inc., and Accordant Healthcare Inc.
     Dr. Marks, a recognized leader in the cancer field, was President and
 Chief Executive Officer of Memorial Sloan-Kettering Cancer Center in New York
 from 1980 to 1999.  Previously Dr. Marks held teaching and research positions
 at Columbia University for 25 years.  In addition, he has served as an advisor
 to the National Institutes of Health, the National Science Foundation, and
 other governmental bodies.  He is a member of the National Academy of Sciences
 and the Institute of Medicine, as well as a Fellow of the American Academy of
 Arts and Sciences.  He has received numerous honors and awards, including the
 President's National Medal of Science.  In addition, he has published more
 than 375 scientific articles in various scholarly journals.
 
     About BioStratum
     BioStratum is a worldwide leader in drug development based on basal lamina
 research.  The Company is developing a pipeline of drugs based on the basal
 lamina's central role in many diseases.  Pyridorin(TM), the Company's lead
 drug candidate, is currently advancing through Phase II clinical trials for
 diabetic kidney disease. BioStratum is working toward having Angiocol(TM) --
 its proprietary anti-angiogenesis drug candidate that dramatically inhibits
 the growth of tumors in animal models of cancer -- enter Phase I clinical
 trials in late 2001.  BioStratum is also developing novel therapeutics for
 other kidney diseases, tissue regeneration, and autoimmune diseases.
 Headquartered in Research Triangle Park, North Carolina, BioStratum's research
 and development operations are further extended through multiple
 collaborations with leading basal lamina research centers.  For further
 information, please visit www.biostratum.com.
 
     CONTACT:
      BioStratum Incorporated
      Mike Klodnicki
      Director of Investor Relations and
      Corporate Communications
      (919) 433-1038
      mklodnicki@BioStratum.com
 
      Feinstein Kean Healthcare
      Harriet Ullman
      (617) 577-8110
      hullman@fkhealth.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X14735637
 
 SOURCE  BioStratum Incorporated